Cargando…

Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells

PURPOSE: Prolactinoma (prolactin-secreting pituitary adenoma) is one of the most common estrogen-related functional pituitary tumors. As an agonist of the dopamine D2 receptor, bromocriptine is used widely to inhibit prolactinoma progression. On the other hand, it is not always effective in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jinxiang, Zhang, Fenglin, Jiang, Lei, Hu, Guohan, Sun, Wei, Zhang, Chenran, Ding, Xuehua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398389/ https://www.ncbi.nlm.nih.gov/pubmed/27488872 http://dx.doi.org/10.4143/crt.2016.017

Ejemplares similares

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013)

Temporal resolution of idiopathic granulomatous mastitis with resumption of bromocriptine therapy for prolactinoma
por: Bouton, Marcia E., et al.
Publicado: (2015)

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
por: Menon, Lakshmi P., et al.
Publicado: (2021)

Effects of hypoxia inducible factor-1α on apoptotic inhibition and glucocorticoid receptor downregulation by dexamethasone in AtT-20 cells
por: Zhang, Chenran, et al.
Publicado: (2015)

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas
por: Xiao, Zhengzheng, et al.
Publicado: (2020)

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas: Erratum
por: Xiao, Zhengzheng, et al.
Publicado: (2022)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

A retrospective study on the aetiology, management, and outcome of brain abscess in an 11-year, single-centre study from China
por: Zhang, Chenran, et al.
Publicado: (2014)

Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma
por: Singh, Pratibha, et al.
Publicado: (2011)

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma
por: Igata, Motoyuki, et al.
Publicado: (2020)

RIZ1: a potential tumor suppressor in glioma
por: Zhang, Chenran, et al.
Publicado: (2015)

Erratum to: RIZ1: a potential tumor suppressor in glioma
por: Zhang, Chenran, et al.
Publicado: (2016)

Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively
por: Tang, Chao, et al.
Publicado: (2019)

Inhibition of Skp2 sensitizes lung cancer cells to paclitaxel
por: Huang, Tonghai, et al.
Publicado: (2017)

Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis
por: Jiang, Yan-Nian, et al.
Publicado: (2007)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Inhibiting MAPK14 showed anti-prolactinoma effect
por: Ding, Qiao-yan, et al.
Publicado: (2020)

Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
por: Chen, Xiaowen, et al.
Publicado: (2020)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
por: Tang, Yiqun, et al.
Publicado: (2023)

Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl-xL signaling pathways
por: Xiao, Zhengzheng, et al.
Publicado: (2021)

The learning curve of endoscopic endonasal transsphenoidal surgery for pituitary adenomas with different surgical complexity
por: Huang, Jinxiang, et al.
Publicado: (2023)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

USP2 is an SKP2 deubiquitylase that stabilizes both SKP2 and its substrates
por: Zhang, Fengwu, et al.
Publicado: (2021)

Effects of RNAi-induced Skp2 inhibition on cell cycle, apoptosis and proliferation of endometrial carcinoma cells
por: Lin, Hao, et al.
Publicado: (2019)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Co-Administration of Curcumin and Bromocriptine Nano-liposomes for Induction of Apoptosis in Lung Cancer Cells
por: Sheikhpour, Mojgan, et al.
Publicado: (2020)

AB086. The effect of Xuanju compound capsule combined with bromocriptine
por: Bian, Jun, et al.
Publicado: (2016)

Treatment of Prolactinoma
por: Inder, Warrick J., et al.
Publicado: (2022)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Overexpression of SKP2 Inhibits the Radiation-Induced Bystander Effects of Esophageal Carcinoma
por: Wang, Xiao-Chun, et al.
Publicado: (2017)

Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
por: Zhang, Qiaoli, et al.
Publicado: (2022)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lit92p8lspimv316f77retmrj1